Search Results - "TALJA, M."

Drug-eluting bioabsorbable stents – An in vitro study by Mikkonen, J., Uurto, I., Isotalo, T., Kotsar, A., Tammela, T.L.J., Talja, M., Salenius, J.-P., Törmälä, P., Kellomäki, M.

“…The aim of this study was to investigate the drug elution properties of novel drug-eluting bioabsorbable stents in vitro with four different drugs:…”
Get full text

Expression of Ki-67, Cyclin D1 and Apoptosis Markers Correlated with Survival in Prostate Cancer Patients Treated by Radical Prostatectomy by AALTOMAA, S, KÄRJÄ, V, LIPPONEN, P, ISOTALO, T, KANKKUNEN, J.-P, TALJA, M, MOKKA, R

“…Objective: The study was designed to analyse the prognostic value of proliferation markers Ki-67 and cyclin D1 and apoptosis in prostate cancer (PC) patients…”
Get full text

Histological grade, perineural infiltration, tumour-infiltrating lymphocytes and apoptosis as determinants of long-term prognosis in prostatic adenocarcinoma by Vesalainen, S, Lipponen, P, Talja, M, Syrjänen, K

“…A series of 325 prostatic adenocarcinomas with a long-term clinical follow-up were subjected to light microscopic analysis of histological prognostic factors,…”
Get more information

Biodegradable urethral stents by Tammela, T.L.J., Talja, M.

Get full text

Reduced α- and β-catenin expression predicts shortened survival in local prostate cancer by AALTOMAA, S, KÄRJÄ, V, LIPPONEN, P, ISOTALO, T, KANKKUNEN, J.-P, TALJA, M, MOKKA, R

“…The aim of this study was to determine the prognostic value of alpha- and beta-catenin expressions in local prostate cancer (PC). One hundred and eighty-one PC…”
Get full text

Long-term use of tamsulosin to treat lower urinary tract symptoms/benign prostatic hyperplasia by Schulman, C C, Lock, T M, Buzelin, J M, Boeminghaus, F, Stephenson, T P, Talja, M

“…The long-term efficacy and safety of 0.4 mg. tamsulosin once daily were assessed in patients with lower urinary tract symptoms/benign prostatic hyperplasia…”
Get more information

A bioabsorbable self-expandable, self-reinforced poly-L-lactic acid urethral stent for recurrent urethral strictures: long-term results by Isotalo, T, Talja, M, Välimaa, T, Törmälä, P, Tammela, T L J

“…Biodegradable urethral stents have been used clinically for some years mainly in order to prevent postoperative urinary retention after minimally invasive…”
Get more information

Crystal structure of 2-[(2-ethyl)phenylamino]pyridine, C13H14N2 by Talja M., Polamo M.

Get full text

Crystal structure of 2-(2,3-dimethylphenylamino)pyridine, C13H14N2 by Polamo M., Talja M.

Get full text

Crystal structure of 2-[2,6-di(methylethyl)phenylamino]pyridine, C17H22N2 by Polamo M., Talja M., Piironen A. J.

Get full text

Viscoelastic memory and self-expansion of self-reinforced bioabsorbable stents by Välimaa, T, Laaksovirta, S, Tammela, T.L.J, Laippala, P, Talja, M, Isotalo, T, Pétas, A, Taari, K, Törmälä, P

“…The possibility to decide the speed and rate of expansion of stents is of great clinical importance by reason of the varying requirements for different…”
Get full text

Crystal structure of trichIoro(phenyI-2-pyridyIamido)phenylimidotungsten( VI), WCl3(C6H5N)(C11H9N2) by Polamo M., Talja M.

Get full text

Biocompatibility of various indwelling double-J stents by Cormio, L, Talja, M, Koivusalo, A, Mäkisalo, H, Wolff, H, Ruutu, M

“…The biocompatibility of 8 double-J stent brands was evaluated both in vivo, by scanning electron microscopy and histological analysis of pig ureters intubated…”
Get more information

Crystal structure of 4-N-phenylisoindolinone, C14H11NO by Polamo M., Talja M.

“…C14H11NO, monoclinic, P121/n1 (No. 14), a = 5.925(4) Å, b = 7.556(2) Å, c = 23.11(1) Å, β = 94.67(5)°, V = 1031.3 Å3, Z = 4, Rgt(F) = 0.055, wRref(F2) = 0.140,…”
Get full text

A double‐blind, randomized, placebo‐controlled pilot study to investigate the effects of finasteride combined with a biodegradable self‐reinforced poly l‐lactic acid spiral stent in patients with urinary retention caused by bladder outlet obstruction from benign prostatic hyperplasia by Isotalo, T., Talja, M., Hellström, P., Perttilä, I., Välimaa, T., Törmälä, P., Tammela, T.L.J.

“…Objective To assess whether patients in acute urinary retention from benign prostatic enlargement can be treated with a combined therapy comprising finasteride…”
Get full text

Crystal structure of 2-(2,6-difluorophenylamino)pyridine, C11H8F2N2 by Polamo M., Talja M.

Get full text

Crystal structure of 2-(2,3-dimethylphenylamino)pyridine, C13H14N2 by Polamo M., Talja M.

“…C13H14N2, monoclinic, P121/n1 (no. 14), a = 11.304(8) Å, b = 7.775(8) Å, c = 13.451(9) Å, β = 113.98(5)°, V = 1080.2 Å3, Z = 4, Rgt(F) = 0.050, wRref(F2) =…”
Get full text

Crystal structure of 2-[(2-ethyl)phenylamino]pyridine, C13H14N2 by Talja M., Polamo M.

“…C13H14N2, monoclinic, P121/c1 (no. 14), a = 11.892(6) Å, b = 7.570(7) Å, c = 13.309(7) Å, β = 112.65(3)°, V = 1105.7 Å3, Z = 4, Rgt(F) = 0.055, wRref(F2) =…”
Get full text

Biodegradable self-reinforced polyglycolic acid spiral stent in prevention of postoperative urinary retention after visual laser ablation of the prostate-laser prostatectomy by Talja, M, Tammela, T, Petas, A, Välimaa, T, Taari, K, Viherkoski, E, Törmälä, P

“…The efficacy and safety of a new biodegradable (self-reinforced polyglycolic acid) spiral stent in securing free voiding despite edema after visual laser…”
Get more information

Crystal structure of 4-N-phenylisoindolinone, C14H11NO by Polamo M., Talja M.

Get full text